{"id":"W4393098859","doi":"10.1016/j.ejca.2024.113958","title":"A randomized, double-blind, phase III study in India to evaluate efficacy, safety, pharmacokinetics (PK), and immunogenicity of ZRC-3277 (pertuzumab biosimilar) in comparison with Perjeta® (pertuzumab) in patients with HER2-positive metastatic breast cancer","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Pertuzumab; Biosimilar; Immunogenicity; Pharmacokinetics; Medicine; Double blind; Pharmacology; Internal medicine; Trastuzumab; Placebo; Immunology; Antibody; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002977151,0.0003925918,0.001493377,0.0006478805,0.00005081029,0.00004601456,0.0003088227,0.00006162432,0.0002488537],"category_scores_gemma":[0.00004725394,0.0002411969,0.0001339309,0.0008572476,0.0003594119,0.0001468276,0.0001227675,0.0008981396,0.000002767856],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002866398,"about_ca_system_score_gemma":0.0002887406,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004208417,"about_ca_topic_score_gemma":0.0005088048,"domain_scores_codex":[0.9949389,0.002480611,0.001486684,0.000425384,0.0002474159,0.0004210824],"domain_scores_gemma":[0.9985348,0.0003992152,0.0004563624,0.0001844374,0.0003295794,0.00009561631],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8960059,0.003992874,0.03800069,0.00008984221,0.002810145,0.0003349922,0.007534238,0.001003849,0.00209655,0.000008068694,0.0001138826,0.04800897],"study_design_scores_gemma":[0.7842218,0.004488316,0.2017941,0.002048185,0.001615096,0.00007555383,0.000750708,0.0003055051,0.003872214,0.000003023808,0.0003551544,0.000470341],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9822463,0.0147187,0.0001781079,0.0007389962,0.000273984,0.001560828,0.0001461865,0.000007733112,0.0001291528],"genre_scores_gemma":[0.9985011,0.0008369731,0.0002837248,0.0002174794,0.00003261361,0.00002626519,0.000007166789,0.00004708122,0.0000476151],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1637934,"threshold_uncertainty_score":0.9835726,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03121014927277414,"score_gpt":0.3622070905831796,"score_spread":0.3309969413104055,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}